Fusion Antibodies PLC (FAB) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.792x

Based on the latest financial reports, Fusion Antibodies PLC (FAB) has a cash flow conversion efficiency ratio of -0.792x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-575.00K ≈ $-69.96 USD) by net assets (GBX726.00K ≈ $88.33 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Fusion Antibodies PLC - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Fusion Antibodies PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read FAB current and long-term liabilities for a breakdown of total debt and financial obligations.

Fusion Antibodies PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fusion Antibodies PLC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Sprott Physical Uranium Trust TO:U-U	0.000x
Centaur Media LSE:CAU	0.103x
Oriole Resources PLC LSE:ORR	-0.058x
East Star Resources PLC LSE:EST	-0.117x
VOLATUS CAPITAL CORP. F:VOY0	N/A
noco-noco Inc. Ordinary Share NASDAQ:NCNC	0.000x
Graphjet Technology NASDAQ:GTI	0.009x
Afine Investments Ltd JSE:ANI	N/A

Annual Cash Flow Conversion Efficiency for Fusion Antibodies PLC (2015–2025)

The table below shows the annual cash flow conversion efficiency of Fusion Antibodies PLC from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Fusion Antibodies PLC.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	GBX669.00K ≈ $81.40	GBX-1.36 Million ≈ $-165.96	-2.039x	-106.65%
2024-03-31	GBX1.79 Million ≈ $218.16	GBX-1.77 Million ≈ $-215.24	-0.987x	+36.87%
2023-03-31	GBX1.12 Million ≈ $136.64	GBX-1.75 Million ≈ $-213.53	-1.563x	-1644.63%
2022-03-31	GBX3.68 Million ≈ $448.24	GBX-330.00K ≈ $-40.15	-0.090x	+63.06%
2021-03-31	GBX4.75 Million ≈ $577.57	GBX-1.15 Million ≈ $-140.04	-0.242x	-602.87%
2020-03-31	GBX4.81 Million ≈ $585.48	GBX-166.00K ≈ $-20.20	-0.034x	+83.18%
2019-03-31	GBX5.35 Million ≈ $651.44	GBX-1.10 Million ≈ $-133.64	-0.205x	-1847.36%
2018-03-31	GBX6.58 Million ≈ $800.00	GBX77.19K ≈ $9.39	0.012x	+153.59%
2017-03-31	GBX1.71 Million ≈ $207.56	GBX-37.37K ≈ $-4.55	-0.022x	-109.21%
2016-03-31	GBX1.46 Million ≈ $177.28	GBX346.57K ≈ $42.17	0.238x	+122.12%
2015-03-31	GBX169.29K ≈ $20.60	GBX-182.05K ≈ $-22.15	-1.075x	--

About Fusion Antibodies PLC

LSE:FAB UK Biotechnology

Market Cap

$193.60K

GBX1.59 Billion GBX

Market Cap Rank

#30829 Global

#1022 in UK

Share Price

GBX14.00

Change (1 day)

+0.00%

52-Week Range

GBX5.80 - GBX19.25

All Time High

GBX213.00